MapLight Therapeutics (MPLT) CMO reports 47,158-share stock sale
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. reported that Chief Medical Officer Erin Pennock Foff sold a total of 47,158 shares of Voting Common Stock over July 15–17, 2026. After these transactions, she directly holds 298,901 shares. Certain sales were executed under a Rule 10b5-1 trading plan adopted on December 29, 2025, while others were mandated "sell to cover" transactions to satisfy statutory tax withholding arising from vesting restricted stock units.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 47,158 shares ($1,734,490)
Net Sell
9 txns
Insider
Foff Erin Pennock
Role
Chief Medical Officer
Sold
47,158 shs ($1.73M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Voting Common Stock | 3,656 | $37.90 | $139K |
| Sale | Voting Common Stock | 9,163 | $36.46 | $334K |
| Sale | Voting Common Stock | 5,865 | $37.26 | $219K |
| Sale | Voting Common Stock | 19 | $37.96 | $721.24 |
| Sale | Voting Common Stock | 7,155 | $36.16 | $259K |
| Sale | Voting Common Stock | 7,845 | $37.04 | $291K |
| Sale | Voting Common Stock | 4,465 | $36.00 | $161K |
| Sale | Voting Common Stock | 8,972 | $36.99 | $332K |
| Sale | Voting Common Stock | 18 | $37.54 | $675.72 |
Holdings After Transaction:
Voting Common Stock — 298,901 shares (Direct)
Footnotes (1)
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.70 to $36.685 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.701 to $37.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.5338 to $36.5273 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.53 to $37.405 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.9075 to $36.9013 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.9082 to $37.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.49 to $37.925 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold: 47,158 shares
Post-transaction holdings: 298,901 shares
Sale date range: July 15–17, 2026
+3 more
6 metrics
Shares sold
47,158 shares
Aggregate Voting Common Stock sales reported for July 15–17, 2026
Post-transaction holdings
298,901 shares
Directly held Voting Common Stock after the final reported sale
Sale date range
July 15–17, 2026
Dates of the reported open-market or private stock sales
Weighted-average sale price example
$36.16 per share
Weighted-average price for 7,155 shares sold on July 15, 2026
Weighted-average sale price example
$37.04 per share
Weighted-average price for 7,845 shares sold on July 15, 2026
Rule 10b5-1 plan adoption date
December 29, 2025
Date the reporting person adopted the Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, weighted average price, sell to cover, restricted stock units, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
sell to cover financial
"to be funded by a sell to cover transaction and does not represent..."
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
restricted stock units financial
"tax withholding obligations in connection with the vesting of the restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
statutory tax withholding obligations financial
"shares required to be sold to cover the statutory tax withholding obligations..."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider stock transactions did MapLight Therapeutics (MPLT) report in this Form 4?
MapLight Therapeutics reported that Chief Medical Officer Erin Pennock Foff sold 47,158 shares of Voting Common Stock between July 15 and 17, 2026. The sales were reported as open-market or private transactions with several weighted-average prices disclosed via detailed footnotes.
Were the MapLight Therapeutics (MPLT) insider sales discretionary or under a plan?
Some transactions were made under a Rule 10b5-1 trading plan adopted on December 29, 2025, as disclosed in a footnote. Other sales are identified as mandatory “sell to cover” transactions to satisfy statutory tax withholding from vesting restricted stock units.
Who is the reporting person in MapLight Therapeutics (MPLT) Form 4 and what is their role?
The reporting person is Erin Pennock Foff, who serves as Chief Medical Officer of MapLight Therapeutics. The Form 4 details her recent sales of Voting Common Stock, the prices involved, and her resulting direct share ownership after the transactions.